NYMXF — Nymox Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- $19.58m
- $19.51m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.299 | 0.116 | 0.005 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.161 | 0.058 | 0.001 | 0 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 10.9 | 13.4 | 11.7 | 12.5 | 6.65 |
Operating Profit | -10.6 | -13.3 | -11.7 | -12.5 | -6.65 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.6 | -13.2 | -11.7 | -12.5 | -6.58 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.6 | -13.2 | -11.7 | -12.5 | -6.58 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.6 | -13.2 | -11.7 | -12.5 | -6.58 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.6 | -13.2 | -11.7 | -12.5 | -6.58 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.175 | -0.191 | -0.159 | -0.153 | -0.074 |